Geriatric Assessment in Older Adults with Multiple Myeloma.
aged
elderly persons
geriatric assessment
hematopoietic stem cell transplantation
multiple myeloma
Journal
Journal of the American Geriatrics Society
ISSN: 1532-5415
Titre abrégé: J Am Geriatr Soc
Pays: United States
ID NLM: 7503062
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
15
08
2018
revised:
01
11
2018
accepted:
07
11
2018
pubmed:
15
12
2018
medline:
2
5
2020
entrez:
15
12
2018
Statut:
ppublish
Résumé
The incidence of myeloma in older adults is increasing, yet little is known about geriatric impairments in these patients. We aimed to examine the prevalence of geriatric impairments in older adults with myeloma and the association between geriatric assessment and autologous stem cell transplant eligibility. Prospective cohort study. Two academic medical centers. A total of 40 adults 65 years and older with newly diagnosed myeloma were enrolled. Participants completed a primarily self-administered geriatric assessment, including measures of functional status, comorbidities, polypharmacy, psychosocial status, social support, quality of life, cognition, and physical performance. Outcomes were autologous stem cell transplant eligibility and receipt. Forty patients enrolled; their mean age was 71 years. Geriatric impairments were common: 62% reported dependence in one or more instrumental activities of daily living (IADL), 76.9% had polypharmacy (four or more medications), and 47.5% had one or more comorbidities. Median time on the Timed Up and Go was 13.3 ± 4.9 seconds. Those considered candidates for autologous stem cell transplant (N = 26) were younger, with fewer comorbidities, better performance status, and faster performance on the Timed Up and Go test. Factors independently associated with receiving autologous stem cell transplant (N = 21) included age and IADL dependence. Impairments in geriatric domains are common in this population, even among those considered to have a good performance status. Geriatric assessment domains are associated with both transplant eligibility and receipt. J Am Geriatr Soc 67:987-991, 2019.
Sections du résumé
BACKGROUND/OBJECTIVES
The incidence of myeloma in older adults is increasing, yet little is known about geriatric impairments in these patients. We aimed to examine the prevalence of geriatric impairments in older adults with myeloma and the association between geriatric assessment and autologous stem cell transplant eligibility.
DESIGN
Prospective cohort study.
SETTING
Two academic medical centers.
PARTICIPANTS
A total of 40 adults 65 years and older with newly diagnosed myeloma were enrolled.
MEASUREMENT
Participants completed a primarily self-administered geriatric assessment, including measures of functional status, comorbidities, polypharmacy, psychosocial status, social support, quality of life, cognition, and physical performance. Outcomes were autologous stem cell transplant eligibility and receipt.
RESULTS
Forty patients enrolled; their mean age was 71 years. Geriatric impairments were common: 62% reported dependence in one or more instrumental activities of daily living (IADL), 76.9% had polypharmacy (four or more medications), and 47.5% had one or more comorbidities. Median time on the Timed Up and Go was 13.3 ± 4.9 seconds. Those considered candidates for autologous stem cell transplant (N = 26) were younger, with fewer comorbidities, better performance status, and faster performance on the Timed Up and Go test. Factors independently associated with receiving autologous stem cell transplant (N = 21) included age and IADL dependence.
CONCLUSION
Impairments in geriatric domains are common in this population, even among those considered to have a good performance status. Geriatric assessment domains are associated with both transplant eligibility and receipt. J Am Geriatr Soc 67:987-991, 2019.
Identifiants
pubmed: 30548581
doi: 10.1111/jgs.15715
pmc: PMC7006442
mid: NIHMS1551177
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
987-991Subventions
Organisme : NIA NIH HHS
ID : R03 AG042374
Pays : United States
Organisme : NCI NIH HHS
ID : K12 CA167540
Pays : United States
Organisme : NIH
Pays : International
Organisme : NCATS NIH HHS
ID : UL1 TR000448
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002345
Pays : United States
Organisme : NCI NIH HHS
ID : K12CA167540
Pays : United States
Informations de copyright
© 2018 The American Geriatrics Society.
Références
Blood Adv. 2017 Jan 4;1(4):282-287
pubmed: 29296944
J Am Geriatr Soc. 2011 Oct;59(10):1837-46
pubmed: 22091497
J Clin Oncol. 2005 May 20;23(15):3412-20
pubmed: 15809451
J Clin Oncol. 1998 Apr;16(4):1582-7
pubmed: 9552069
J Clin Oncol. 2014 Aug 20;32(24):2595-603
pubmed: 25071125
Gerontologist. 1969 Autumn;9(3):179-86
pubmed: 5349366
Blood. 2015 Mar 26;125(13):2068-74
pubmed: 25628469
J Clin Oncol. 2012 May 20;30(15):1829-34
pubmed: 22508806
Leuk Lymphoma. 2016;57(4):789-96
pubmed: 26377031
J Geriatr Psychiatry Neurol. 1995 Oct;8(4):238-42
pubmed: 8561839
J Affect Disord. 1998 Mar;48(2-3):207-14
pubmed: 9543211
J Clin Oncol. 1984 Mar;2(3):187-93
pubmed: 6699671
Blood. 2013 May 23;121(21):4287-94
pubmed: 23550038
Haematologica. 2016 Sep;101(9):1110-9
pubmed: 27479825
Bone Marrow Transplant. 2015 Feb;50(2):209-15
pubmed: 25387088
Biol Blood Marrow Transplant. 2013 Mar;19(3):429-34
pubmed: 23160006
Am J Epidemiol. 2007 Mar 15;165(6):710-8
pubmed: 17182981
J Clin Oncol. 2013 Nov 1;31(31):3877-82
pubmed: 24062399
Blood. 2015 Jan 8;125(2):410-2
pubmed: 25573972
J Am Geriatr Soc. 1991 Feb;39(2):142-8
pubmed: 1991946
J Clin Oncol. 2002 Jan 15;20(2):494-502
pubmed: 11786579
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Cancer. 2012 Jul 1;118(13):3377-86
pubmed: 22072065
Haematologica. 2017 May;102(5):910-921
pubmed: 28154088
Bone Marrow Transplant. 2015 Aug;50(8):1075-82
pubmed: 25961765
Eur J Haematol. 2018 Mar;100(3):273-278
pubmed: 29239009
J Natl Cancer Inst. 2015 May 28;107(8):null
pubmed: 26023094
Acta Oncol. 2014 Mar;53(3):289-96
pubmed: 24134505
J Clin Oncol. 2011 Sep 1;29(25):3457-65
pubmed: 21810685